The Company reported positive pivotal Phase 3 data in adolescents two months ago confirming the immunogenicity and safety profile observed in adults1.There...
QIAGEN announced a plan to return up to approximately $300 million (maximum EUR 273 million) to shareholders through a synthetic share repurchase tha...
QIAGEN announced a strategic plan to step up investments over the next five years in its market-leading QIAGEN Digital Insights (QDI) business. These inve...
The transformative point of care solution will complement Roche’s centralised diagnostics portfolio across Clinical Chemistry, Immunochemistry, Coa...
The European Patent office granted patent No. 3105587 titled 'Method of Qualifying of Cells' for a method of qualifying whether a cell population is a suit...
Glaucoma is the cause of visual impairment or blindness in four percent of the total number of patients in the Netherlands1. Among these, primary open-angl...
The first patient was randomized in China in the NATiV3 Phase III clinical trial, triggering a milestone payment of $3 million from CTTQ to Inventiva.&nb...
CARMEN-LC03 trial did not meet dual primary endpoint of improving progression-free survival; tusamitamab ravtansine clinical development program will be ...
Parse Biosciences, a leading provider of easily accessible and scalable solutions for single-cell sequencing, announced today that the company has raised $...
Roivant (Nasdaq: ROIV) announced the completion of the previously announced acquisition by Roche (SIX: RO, ROG; OTCQX: RHHBY) of Telavant, for an upf...
In addition, Lonza, Medivir's partner for process development and manufacture of drug substance, has developed a process suitable for commercial manufactur...
Macrogen Europe is seeking to expand within Switzerland from its foothold in Basel with its Sanger sequencing laborato...
The significant milestone marks the first result of the company's strategic partnership2 with VIB, Flanders' leading life sciences institute, and potential...
RoslinCT, a cell and gene therapy Contract Development and Manufacturing Organisation (‘CDMO’) dedicated to developing therapies for patients w...
© 2025 Biopharma Boardroom. All Rights Reserved.
